Alpha 2.0
Login Register
» Journals » CPT Pharmacometrics Syst Pharmacol

Cpt: Pharmacometrics & Systems Pharmacology

CPT: pharmacometrics & systems pharmacology is a peer-reviewed journal that focuses on the application of mathematical and computational modeling techniques in pharmacology and drug development. It publishes innovative research articles, reviews, and perspectives that explore the integration of pharmacokinetics, pharmacodynamics, and systems biology to optimize drug therapy and improve patient outcomes.
Details
Abbr. CPT Pharmacometrics Syst Pharmacol
Publisher Wiley
Start 2012
End Continuing
Frequency Monthly
e-ISSN 2163-8306
Country United States
Language English
Specialty Pharmacology
Metrics
h-index / Ranks: 6702 55
SJR / Ranks: 3964 975
CiteScore / Ranks: 3928 5.90
JIF / Ranks: 2766 3.5
Recent Articles
1.
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery
Wen H, Sadiq M, Friberg L, Svensson E
CPT Pharmacometrics Syst Pharmacol . 2025 Mar; PMID: 40087843
Predicting human lung exposure with reasonable certainty of orally inhaled drugs based on preclinical studies remains a challenge for drug development. We have developed a comprehensive physiologically based pharmacokinetic (PBPK)...
2.
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling
Wijk M, Wasmann R, Jacobson K, Svensson E, Denti P
CPT Pharmacometrics Syst Pharmacol . 2025 Mar; PMID: 40067154
Proper handling of data below the lower limit of quantification (BLQ) is crucial for accurate pharmacokinetic parameter estimation. The M3 method proposed by Beal uses a likelihood-based approach that is...
3.
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB-02) in Patients With Advanced Solid Tumors
Jiang C, Ren F, Zhang M, Lu Q, Zeng S, Yang G, et al.
CPT Pharmacometrics Syst Pharmacol . 2025 Mar; PMID: 40067130
Fanastomig (also known as EMB-02) is a bispecific antibody targeting programmed cell death protein-1(PD-1) and lymphocyte activation gene-3 (LAG-3), developed for the treatment of advanced solid tumors. A first-in-human (FIH)...
4.
Genotype, Ethnicity, and Drug-Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin-I Story
Ujihira Y, Tan S, Scotcher D, Galetin A
CPT Pharmacometrics Syst Pharmacol . 2025 Mar; PMID: 40065524
Coproporphyrin-I (CP-I) is a selective endogenous biomarker of organic anion-transporting polypeptide (OATP)1B. Multiple CP-I PBPK models with differing input parameters have been reported so far. This study proposed a harmonized...
5.
Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit
Arrington L, van Dijkman S, Plan E, Karlsson M
CPT Pharmacometrics Syst Pharmacol . 2025 Mar; PMID: 40045658
Approximately 15% of patients suspected of having Parkinson's disease (PD) present dopamine active transporter (DaT) scans without evidence of dopaminergic deficits (SWEDD), most of which will never develop PD. Leveraging...
6.
Population Pharmacokinetic/Pharmacodynamic and Exposure-Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema
Garcia R, Cheng S, Glassman F, Sharma A, De Miguel-Lillo B, Wiens M, et al.
CPT Pharmacometrics Syst Pharmacol . 2025 Mar; PMID: 40042097
Hereditary angioedema (HAE) is a rare genetic disease that manifests as recurrent, unpredictable, and potentially life-threatening attacks of angioedema. Garadacimab is a first-in-class, fully human, monoclonal antibody targeting activated factor...
7.
Postmarketing Assessment of Antibody-Drug Conjugates: Proof-of-Concept Using Model-Based Meta-Analysis and a Clinical Utility Index Approach
Asiimwe I, Chtiba N, Mouksassi S, Pillai G, Peter R, Yuen E, et al.
CPT Pharmacometrics Syst Pharmacol . 2025 Mar; PMID: 40040312
Antibody-drug conjugates (ADCs) are a promising class of targeted cancer therapies. However, they need careful dose optimization to maximize effectiveness and minimize side effects. Sometimes, safety issues may only become...
8.
Evaluation of Adefovir PBPK Model to Assess Biomarker-Informed OAT1 Drug-Drug Interaction and Effect of Chronic Kidney Disease
Tan S, Wu H, Rostami-Hodjegan A, Scotcher D, Galetin A
CPT Pharmacometrics Syst Pharmacol . 2025 Mar; PMID: 40033714
Evaluation of transporter-mediated drug-drug interactions (DDI) with endogenous biomarkers, coupled with physiologically-based pharmacokinetic modeling (PBPK) is envisioned to replace or reduce dedicated DDI clinical trials with clinical probe substrates. The...
9.
Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET-Guided Verification
van der Gaag S, Jordens T, Yaqub M, Grijseels R, van Valkengoed D, de Langen E, et al.
CPT Pharmacometrics Syst Pharmacol . 2025 Feb; PMID: 40009553
Osimertinib, a tyrosine kinase inhibitor (TKI), treats non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. However, its efficacy may vary due to heterogeneous drug distribution, assessable...
10.
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population
Patel Y, Orogun L, Yocum N, Rodino-Klapac L, East L
CPT Pharmacometrics Syst Pharmacol . 2025 Feb; PMID: 40009522
Duchenne muscular dystrophy (DMD) is characterized by progressive, irreversible muscle damage that usually leads to premature death from cardiac or respiratory failure. Eteplirsen is a phosphorodiamidate morpholino oligomer and the...